Premium
The future of specific immunotherapy: strategies and challenges for the next generation of allergy vaccines
Author(s) -
Sørensen P.
Publication year - 2011
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2011.02644.x
Subject(s) - immunotherapy , medicine , allergy , immunology , oral immunotherapy , intensive care medicine , immune system
To cite this article: Sørensen P. The future of specific immunotherapy: strategies and challenges for the next generation of allergy vaccines. Allergy 2011; 66 (Suppl. 95): 63–65. Abstract The use of specific immunotherapy (SIT) for allergic disorders has recently been extended by introduction of a convenient, tablet‐based, disease‐modifying vaccine against grass pollen allergy. Allergy immunotherapy tablet (AIT) programmes targeting house dust mite and other allergies are currently in late‐phase development. Next‐generation allergy vaccines can have optimised potency and onset of action without compromising safety or convenience. Key to achieving these objectives is a combination of evidence‐based mode‐of‐action studies and biomarker‐centric translational research approaches. This will rely on using biobank and bioinformatics resources for multi‐omic characterisations of the ‘immunome’ of allergic disease. Other important areas are ongoing paediatric trials and long‐term studies in adults for further defining the potential role of SIT in allergic disease and primary prevention of asthma. Finally, combining cellular‐ and serological‐based assays, and developments in targeted delivery platforms and component‐resolved diagnostics will lead to increased ability to stratify patients, with more personalised diagnosis and treatment.